Received May 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMXB094A | — |
LPN reports a patient in their clinic who received the meningococcal reconstitution liquid only and never received the powder of Menveo (2 vial).; LPN reports a patient in their clinic who received the meningococcal reconstitution liquid only and never received the powder of Menveo (2 vial).; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 23-month-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMXB094A, expiry date 30-SEP-2027) for prophylaxis. On 12-MAY-2026, the patient received Menveo. On 12-MAY-2026, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: LPN reports a patient in their clinic who received the meningococcal reconstitution liquid only and never received the powder of Menveo (2 vial).) and inappropriate dose of vaccine administered (Verbatim: LPN reports a patient in their clinic who received the meningococcal reconstitution liquid only and never received the powder of Menveo (2 vial).). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 12-MAY-2026 The nurse reported that how we could administer the powder itself, could reconstitute it with sterile saline water, did need to revaccinate this patient.